SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-095676
Filing Date
2022-04-05
Accepted
2022-04-05 09:01:08
Documents
14
Period of Report
2022-04-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d324074d8k.htm   iXBRL 8-K 32874
2 EX-10.1 d324074dex101.htm EX-10.1 364186
6 GRAPHIC g324074g0405004336602.jpg GRAPHIC 2115
  Complete submission text file 0001193125-22-095676.txt   616426

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20220401.xsd EX-101.SCH 2895
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20220401_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20220401_pre.xml EX-101.PRE 11287
8 EXTRACTED XBRL INSTANCE DOCUMENT d324074d8k_htm.xml XML 3406
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 22805344
SIC: 8071 Services-Medical Laboratories